{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"familial-hyperaldosteronism-type-ii","columns":[{"gene":"","key":"population-f031d82b7a7c6d6e6344","label":"Hyperaldosteronism, familial, type II","mondoId":"MONDO:0011576","onsetQualifier":null,"originColumnKey":"MONDO:0011576/OMIM:605635","originalViews":[{"key":"MONDO:0011576/OMIM:605635","label":"Hyperaldosteronism, familial, type II","scopeLabel":"OMIM:605635","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["a2f3bc99873738c625b7ea420468f1f6d4b0c97c5540d1c6875624f0d5317f0b","af5d608e31324f9a8a03b360d63129e20f7a5a018480d4069f43794a493aaf53","c08055c36aea476374f8720aa3745a95e11d27d97c00579e0bc816b55f4dbb0b"],"recordQualifiers":{},"scopeLabel":"OMIM:605635","sourceIds":["OMIM:605635"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."},{"gene":"","key":"population-c51d4182061b13b95b04","label":"Familial hyperaldosteronism type II","mondoId":"MONDO:0011576","onsetQualifier":null,"originColumnKey":"MONDO:0011576/ORPHA:404","originalViews":[{"key":"MONDO:0011576/ORPHA:404","label":"Familial hyperaldosteronism type II","scopeLabel":"ORPHA:404","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["1ecbb80380ab4ad4d26545b7c4905d29750b8cdbcf9ed017b992778411e9c10e","1fd04e298cc2994c2b1a258e1ee5029865674922e52c370e68dd47dd81c87c19","2993abb7037d86c4e3ffefa8a38fdf86bd899ca8b242338a6b759520cc9bee44","37543ef4ec744906856b0a3172accc917ab6dde3fcd1a25cd713b432c105f036","3905c0229994206beaeb73a875eb09a3dc4cda9d0a8f3db6ea8d7ff7ab9e7a92","538f15dad9a60f9d97863316c5fc898cec141b9f45b73cf9b3441d49f0818fb8","5665bef0afb3f402c94fe92a569194a1bd6db80388f8d86fdbcef67b56217612","689a6777876c9106ddcec170fb83988434234c63724641bb0db804c5f6b981d7","76325c3465519656145c2d4bdd8d049bdbfd096cdc0227c1c81509fd45a14f56","802ddd285aff994cbaf00430556e975c1a3d01e1f155c8714ac6974deae32851","95ef2a925ef5b4fd93b5db980c5bf45d2f517f1d045baa70ac42e3e0af41b99b","995bf2a34c4d812ee00b613217c4861b2f4d060b343ee00120509eecae5a0e93","d7f0fcaed4d6b08c84a4f1bbed55add5e57139f87625fd6e69330b2d36caf74a","ead4436ce30007f4f6fbf842390a3cfc81b6bc0ff160d782773b416ec3040724"],"recordQualifiers":{},"scopeLabel":"ORPHA:404","sourceIds":["ORPHA:404"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-f031d82b7a7c6d6e6344","population-c51d4182061b13b95b04"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0040084","HP:0008221","HP:0011739","HP:0000421","HP:0011740","HP:0002315","HP:0000822"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":2,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":17,"sourceGroups":{"orphanet":14,"published":3}},"features":[{"hpoId":"HP:0040084","label":"Abnormal circulating renin concentration","primary":true},{"hpoId":"HP:0008221","label":"Adrenal hyperplasia","primary":true},{"hpoId":"HP:0011739","label":"Dexamethasone-suppressible primary hyperaldosteronism","primary":true},{"hpoId":"HP:0000421","label":"Epistaxis","primary":true},{"hpoId":"HP:0011740","label":"Glucocortocoid-insensitive primary hyperaldosteronism","primary":true},{"hpoId":"HP:0002315","label":"Headache","primary":true},{"hpoId":"HP:0000822","label":"Hypertension","primary":true},{"hpoId":"HP:0002900","label":"Hypokalemia","primary":false},{"hpoId":"HP:0000859","label":"Increased circulating aldosterone concentration","primary":false},{"hpoId":"HP:0002170","label":"Intracranial hemorrhage","primary":false},{"hpoId":"HP:0200114","label":"Metabolic alkalosis","primary":false},{"hpoId":"HP:0001324","label":"Muscle weakness","primary":false},{"hpoId":"HP:0002018","label":"Nausea","primary":false},{"hpoId":"HP:0011746","label":"Secretory adrenocortical adenoma","primary":false},{"hpoId":"HP:0000360","label":"Tinnitus","primary":false}],"ledeHtml":"A heritable form of primary aldosteronism (PA) characterized by hypertension of varying severity, non-glucocorticoid remediable hyperaldosteronism, variable hypokalemia, low plasma renin activity (PRA) and increased aldosterone-to-renin ratio.","mondoId":"MONDO:0011576","node":{"canonicalSlug":"familial-hyperaldosteronism-type-ii","comparisons":[{"documentSha256":"a61a25992a72213c42519d85797f58b35a4bdb8d9aff68aae91e0cb3c0c7cbfb","key":"legacy-familial-hyperaldosteronism-type-ii","kind":"legacy","label":"familial hyperaldosteronism type II","memberIds":["MONDO:0011576"],"mondoId":"MONDO:0011576","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/familial-hyperaldosteronism-type-ii.a61a25992a72213c42519d85797f58b35a4bdb8d9aff68aae91e0cb3c0c7cbfb.json"},{"documentSha256":"b66bb61f97ca3c42341251bd31ee4a548a6ed936ddf88dfd22fe9cd76a0aa52e","key":"expanded-adrenal-gland-neoplasm","kind":"expanded","label":"adrenal gland neoplasm","memberIds":["MONDO:0002814","MONDO:0002817","MONDO:0003606","MONDO:0003924","MONDO:0004202","MONDO:0004477","MONDO:0004974","MONDO:0006075","MONDO:0006076","MONDO:0006103","MONDO:0006174","MONDO:0006288","MONDO:0006321","MONDO:0006408","MONDO:0006639","MONDO:0007540","MONDO:0008734","MONDO:0009050","MONDO:0011576","MONDO:0016505","MONDO:0019615","MONDO:0021227","MONDO:0021237","MONDO:0021312","MONDO:0021468","MONDO:0021511","MONDO:0024868","MONDO:0035540","MONDO:0036591","MONDO:0044767"],"mondoId":"MONDO:0021227","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-b66bb61f97ca3c423412.b66bb61f97ca3c42341251bd31ee4a548a6ed936ddf88dfd22fe9cd76a0aa52e.json"},{"documentSha256":"43a80b93c19f2aebe625ef5ea18c3cd0b59ed004ce48da183812054416e9bb9a","key":"expanded-familial-hyperaldosteronism","kind":"expanded","label":"familial hyperaldosteronism","memberIds":["MONDO:0007080","MONDO:0011576","MONDO:0013359","MONDO:0014200","MONDO:0014875","MONDO:0016525"],"mondoId":"MONDO:0016525","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-43a80b93c19f2aebe625.43a80b93c19f2aebe625ef5ea18c3cd0b59ed004ce48da183812054416e9bb9a.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Familial hyperaldosteronism type II","originalSourceId":"ORPHA:404","paragraphs":["A heritable form of primary aldosteronism (PA) characterized by hypertension of varying severity, non-glucocorticoid remediable hyperaldosteronism, variable hypokalemia, low plasma renin activity (PRA) and increased aldosterone-to-renin ratio."],"rawAttribution":"MONDO:0011576","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-25T03:38:50Z","upstream":"MONDO:0011576","url":"https://rarediseases.info.nih.gov/diseases/2789"},"ownColumnKeys":["population-f031d82b7a7c6d6e6344","population-c51d4182061b13b95b04"],"publication":"published","relationships":[{"kind":"parent","label":"familial hyperaldosteronism","mondoId":"MONDO:0016525","slug":"familial-hyperaldosteronism"},{"kind":"parent","label":"adrenal cortex neoplasm","mondoId":"MONDO:0036591","slug":"adrenal-cortex-neoplasm"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"range","key":"1ecbb80380ab4ad4d26545b7c4905d29750b8cdbcf9ed017b992778411e9c10e","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000421","is_excluded":false,"label":"Epistaxis","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"1fd04e298cc2994c2b1a258e1ee5029865674922e52c370e68dd47dd81c87c19","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0008221","is_excluded":false,"label":"Adrenal hyperplasia","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2993abb7037d86c4e3ffefa8a38fdf86bd899ca8b242338a6b759520cc9bee44","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002900","is_excluded":false,"label":"Hypokalemia","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"37543ef4ec744906856b0a3172accc917ab6dde3fcd1a25cd713b432c105f036","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0011739","is_excluded":true,"label":"Dexamethasone-suppressible primary hyperaldosteronism","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3905c0229994206beaeb73a875eb09a3dc4cda9d0a8f3db6ea8d7ff7ab9e7a92","raw":{"aspect":"P","body_system":"ear","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000360","is_excluded":false,"label":"Tinnitus","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"538f15dad9a60f9d97863316c5fc898cec141b9f45b73cf9b3441d49f0818fb8","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001324","is_excluded":false,"label":"Muscle weakness","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5665bef0afb3f402c94fe92a569194a1bd6db80388f8d86fdbcef67b56217612","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002018","is_excluded":false,"label":"Nausea","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"689a6777876c9106ddcec170fb83988434234c63724641bb0db804c5f6b981d7","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0040084","is_excluded":false,"label":"Abnormal circulating renin concentration","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"76325c3465519656145c2d4bdd8d049bdbfd096cdc0227c1c81509fd45a14f56","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002315","is_excluded":false,"label":"Headache","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"802ddd285aff994cbaf00430556e975c1a3d01e1f155c8714ac6974deae32851","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0011746","is_excluded":false,"label":"Secretory adrenocortical adenoma","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"95ef2a925ef5b4fd93b5db980c5bf45d2f517f1d045baa70ac42e3e0af41b99b","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002170","is_excluded":false,"label":"Intracranial hemorrhage","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"995bf2a34c4d812ee00b613217c4861b2f4d060b343ee00120509eecae5a0e93","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0011740","is_excluded":false,"label":"Glucocortocoid-insensitive primary hyperaldosteronism","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"a2f3bc99873738c625b7ea420468f1f6d4b0c97c5540d1c6875624f0d5317f0b","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:605635","disease_name":"Hyperaldosteronism, familial, type II","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000822","is_excluded":false,"label":"Hypertension","onset_id":null,"reference":"PMID:29403012","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"af5d608e31324f9a8a03b360d63129e20f7a5a018480d4069f43794a493aaf53","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:605635","disease_name":"Hyperaldosteronism, familial, type II","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0002900","is_excluded":false,"label":"Hypokalemia","onset_id":null,"reference":"PMID:29403012","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"c08055c36aea476374f8720aa3745a95e11d27d97c00579e0bc816b55f4dbb0b","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:605635","disease_name":"Hyperaldosteronism, familial, type II","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0000859","is_excluded":false,"label":"Increased circulating aldosterone concentration","onset_id":null,"reference":"PMID:29403011","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"d7f0fcaed4d6b08c84a4f1bbed55add5e57139f87625fd6e69330b2d36caf74a","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040280","hpo_id":"HP:0000822","is_excluded":false,"label":"Hypertension","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ead4436ce30007f4f6fbf842390a3cfc81b6bc0ff160d782773b416ec3040724","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:404","disease_name":"Familial hyperaldosteronism type II","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0200114","is_excluded":false,"label":"Metabolic alkalosis","onset_id":null,"reference":"ORPHA:404","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/2789\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0011576\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>MONDO:0011576</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>A heritable form of primary aldosteronism (PA) characterized by hypertension of varying severity, non-glucocorticoid remediable hyperaldosteronism, variable hypokalemia, low plasma renin activity (PRA) and increased aldosterone-to-renin ratio.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/2789\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"familial-hyperaldosteronism-type-ii","sourceDocuments":[{"name":"GARD: Familial hyperaldosteronism type II","reviewed":null,"source_release":"2026-10-25T03:38:50Z","url":"https://rarediseases.info.nih.gov/diseases/2789"},{"name":"MONDO: familial hyperaldosteronism type II","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0011576"}],"sourceNote":"","synonyms":["familial adrenal adenoma","familial hyperaldosteronism type 2","FH-II","FH2","FHII","HALD2"],"takeawayHtml":"","title":"familial hyperaldosteronism type II"},"schemaVersion":1}
